Topical Janus Kinase Inhibitors: A Review of Applications in Dermatology

    Anna-Marie Hosking, Margit Juhász, Natasha Atanaskova Mesinkovska
    Studysummary This review discusses the efficacy and safety of topical JAK inhibitors for inflammatory skin conditions, reporting modest benefits in psoriasis and atopic dermatitis but mixed results for vitiligo and inconclusive data for alopecia areata.
    Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
    Read the full study on jaad.org →
    Discuss this study in the Community →

    Research cited in this study 9

    1. A Case of Topical Ruxolitinib Treatment Failure in Alopecia Areata Journal of cutaneous medicine and surgery · 2017
    2. Topical Janus Kinase Inhibitors for the Treatment of Pediatric Alopecia Areata Journal of the American Academy of Dermatology · 2017
    3. Janus Kinase Inhibitors in Dermatology: A Systematic Review Journal of the American Academy of Dermatology · 2017
    4. JAK Inhibitors in Dermatology: The Promise of a New Drug Class Journal of the American Academy of Dermatology · 2017
    5. Safety and Efficacy of the JAK Inhibitor Tofacitinib Citrate in Patients with Alopecia Areata JCI insight · 2016
    6. Oral Ruxolitinib Induces Hair Regrowth in Patients with Moderate-to-Severe Alopecia Areata JCI insight · 2016
    7. Topical Ruxolitinib for the Treatment of Alopecia Universalis JAMA dermatology · 2015
    8. Reversal of Alopecia Areata Following Treatment With the JAK1/2 Inhibitor Baricitinib EBioMedicine · 2015
    9. Killing Two Birds with One Stone: Oral Tofacitinib Reverses Alopecia Universalis in a Patient with Plaque Psoriasis Journal of Investigative Dermatology · 2014

    Related research 1

    1. Inhibiting Janus Kinases to Treat Alopecia Areata Nature medicine · 2014